Skip to Main Content

Latest News

Advertisement
Advertise Here
January 24, 2011
Volume 89, Number 04
pp. 9 - 9

Pharmaceuticals: GSK Takes $3.5 Billion Charge For Marketing, Product Liability Cases

Michael McCoy

  • Print this article
  • Email the editor

Latest News



October 28, 2011

Speedy Homemade-Explosive Detector

Forensic Chemistry: A new method could increase the number of explosives detected by airport screeners.

Solar Panel Makers Cry Foul

Trade: U.S. companies complain of market dumping by China.

Novartis To Cut 2,000 Jobs

Layoffs follow similar moves by Amgen, AstraZeneca.

Nations Break Impasse On Waste

Environment: Ban to halt export of hazardous waste to developing world.

New Leader For Lawrence Livermore

Penrose (Parney) Albright will direct DOE national lab.

Hair Reveals Source Of People's Exposure To Mercury

Toxic Exposure: Mercury isotopes in human hair illuminate dietary and industrial sources.

Why The Long Fat?

Cancer Biochemistry: Mass spectrometry follows the metabolism of very long fatty acids in cancer cells.

Text Size A A

GlaxoSmithKline will take a fourth-quarter 2010 legal charge of $3.5 billion related to consumer lawsuits and a U.S. investigation of the company’s marketing practices. The charge is the third big financial hit GSK has taken since mid-2010 due to questionable marketing and manufacturing practices.

The new charge primarily relates to product liability cases over the diabetes drug Avandia and to an investigation by the U.S. Attorney’s Office into the firm’s overall sales and promotional practices, according to GSK. “We recognize that this is a significant charge, but we believe the approach we are taking to resolve long-standing legal matters is in the company’s best interests,” says P. D. Villarreal, GSK’s senior vice president for global litigation.

In a research report, Morgan Stanley stock analysts say they suspect the bulk of the write-down relates to the U.S. government’s investigation. “Enforcement risk for the industry remains high and has an important impact on revenue momentum, profitability, and balance sheets,” they write.

The analysts figure that most of the Avandia cases were covered by a $2.4 billion charge the company took in the second quarter. Avandia has been under scrutiny for some time because of its potential cardiovascular side effects. In September, FDA said it would substantially limit use of the drug.

The earlier charge, announced in July, also covered product liability and antitrust litigation over Paxil, an antidepressant, and payments to the U.S. government related to manufacturing violations at a plant in Cidra, P.R. In November, GSK paid out $750 million to settle criminal and civil cases connected to the Cidra plant.—

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2011 American Chemical Society
  • Print this article
  • Email the editor

Services & Tools

ACS Resources

ACS is the leading employment source for recruiting scientific professionals. ACS Careers and C&EN Classifieds provide employers direct access to scientific talent both in print and online. Jobseekers | Employers

» Join ACS

Join more than 161,000 professionals in the chemical sciences world-wide, as a member of the American Chemical Society.
» Join Now!